Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $1,881,638.07 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 141,583 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $13.29, for a total value of $1,881,638.07. Following the transaction, the chief operating officer owned 516,610 shares in the company, valued at approximately $6,865,746.90. This trade represents a 21.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Julie Rubinstein also recently made the following trade(s):

• On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $12.96, for a total value of $247,017.60.
• On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.79, for a total value of $457,617.39.
• On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.68, for a total transaction of $285,672.80.
• On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.67, for a total transaction of $484,845.47.
• On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $16.00, for a total transaction of $495,056.00.

Adaptive Biotechnologies Stock Performance

Shares of NASDAQ:ADPT opened at $13.17 on Monday. The company has a 50 day moving average price of $16.55 and a two-hundred day moving average price of $15.89. The company has a market capitalization of $2.03 billion, a PE ratio of -32.92 and a beta of 2.19. Adaptive Biotechnologies Corporation has a 52 week low of $6.68 and a 52 week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company had revenue of $71.68 million for the quarter, compared to analysts’ expectations of $59.38 million. During the same period last year, the firm posted ($0.23) earnings per share. The business’s quarterly revenue was up 51.0% compared to the same quarter last year. On average, sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Institutional Trading of Adaptive Biotechnologies

A number of institutional investors have recently made changes to their positions in the business. XTX Topco Ltd bought a new stake in Adaptive Biotechnologies during the 2nd quarter worth about $793,000. SG Americas Securities LLC boosted its stake in shares of Adaptive Biotechnologies by 53.2% during the 2nd quarter. SG Americas Securities LLC now owns 37,328 shares of the company’s stock worth $435,000 after buying an additional 12,963 shares during the last quarter. Allianz Asset Management GmbH grew its holdings in shares of Adaptive Biotechnologies by 305.8% in the 3rd quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock valued at $4,814,000 after acquiring an additional 242,474 shares in the last quarter. Hillsdale Investment Management Inc. acquired a new stake in shares of Adaptive Biotechnologies in the second quarter valued at about $6,618,000. Finally, Envestnet Asset Management Inc. acquired a new stake in shares of Adaptive Biotechnologies in the second quarter valued at about $467,000. Institutional investors own 99.17% of the company’s stock.

Analyst Upgrades and Downgrades

ADPT has been the subject of several recent analyst reports. Morgan Stanley began coverage on Adaptive Biotechnologies in a report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price target for the company. JPMorgan Chase & Co. lifted their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Friday, February 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a research note on Friday, February 6th. Finally, TD Cowen restated a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $18.25.

Adaptive Biotechnologies News Summary

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
• Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
• Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.